Hotaka Ishizu
Hokkaido University
Quality of lifeVitamin D and neurologyInternal medicineRadiologyUrologySurgeryMagnetic resonance imagingBone remodelingIntensive care medicineRheumatologyFemoral neckDenosumabZoledronic acidOsteoporosisBone mineralCombination therapyBisphosphonateTeriparatideOsteonecrosis of the jawDiscontinuationFemoral headEldecalcitolRomosozumabInsufficiency fractureFemur fracturePostmenopausal osteoporosisAdolescent patientRadiographyOrthopedic surgeryMedicine
4Publications
1H-index
1Citations
Publications 5
Newest
#1Hotaka Ishizu (Hokkaido University)H-Index: 1
#2Kosuke Arita (Hokkaido University)
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 5 authors...
Introduction: Osteoporosis is characterized by the fragility of bones, leading to fractures and, consequently, the deterioration of functional capacity and quality of life. Postmenopausal women, in particular, are prone to osteoporosis and often require anti-osteoporosis treatment. In the last few decades, various anti-osteoporosis drugs have been approved for clinical use. In an aging society, osteoporosis cannot be treated using a single agent; therefore, switching therapy is an important trea...
Source
#1Tomohiro Shimizu (Hokkaido University)H-Index: 11
#2Kosuke Arita (Hokkaido University)
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 10 authors...
Purpose We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Methods Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or ...
Source
#1Yumejiro Nakamura (Hokkaido University)H-Index: 1
#2Tomohiro Shimizu (Hokkaido University)H-Index: 11
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 8 authors...
Introduction We aimed to compare the efficacy after switching from either bisphosphonates (BPs) or non-BPs (NBPs) to combination therapies of denosumab (DMAb) or zoledronic acid (Zol) with eldecalcitol (ELD) in bone mineral density (BMD) and bone metabolism and investigate the prognostic and risk factors of side effects of this therapy. Materials and methods One-hundred forty-eight patients with postmenopausal osteoporosis were recruited; their therapy was switched from BPs or NBPs to Zol or DMA...
Source
#1Tomohiro Shimizu (Hokkaido University)H-Index: 11
#2Shunichi Yokota (Hokkaido University)H-Index: 1
Last. Daisuke Takahashi (Hokkaido University)H-Index: 11
view all 8 authors...
BACKGROUND There is evidence that the cause of primary osteoarthritis (OA) is related to the changes in subchondral bone; however, the influence of subchondral insufficiency fracture (SIF) of the femoral head on the degeneration of the hip joint and the prognostic factors related to joint degeneration remain unclear. The objectives of this study were (1) to investigate the natural history of joint space width after the occurrence of SIF and (2) to investigate the associations between joint space...
Source
#1Hotaka Ishizu (Hokkaido University)H-Index: 1
#2Tomohiro Shimizu (Hokkaido University)H-Index: 11
Last. Norimasa Iwasaki (Hokkaido University)H-Index: 45
view all 7 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.